EVI5L 抗体 (AA 642-794)
Quick Overview for EVI5L 抗体 (AA 642-794) (ABIN1817740)
抗原
See all EVI5L 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 642-794
- 
                                            特异性
- Human EVI5L.
- 
                                            纯化方法
- Affinity purified
- 
                                            免疫原
- 
                        A recombinant human EVI5L protein 642-794aa (BC014111).
 Type of Immunogen: Recombinant protein
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- Approved: ELISA (1:20000 - 1:80000), IHC (1:100 - 1:500), WB (1:1000 - 1:2000)
- 
                                            说明
- 
                        Target Species of Antibody: Human 
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- Lot specific
- 
                                            缓冲液
- PBS, pH 7.4, 0.02 % sodium azide
- 
                                            储存液
- Sodium azide
- 
                                            注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C
- 
                                            储存方法
- Store at -20°C for up to 1 year.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - EVI5L (Ecotropic Viral Integration Site 5-Like (EVI5L))
- 
                                            别名
- EVI5L
- 
                                            背景
- 
                        Name/Gene ID: EVI5L
 Synonyms: EVI5L, EVI5-like protein
- 
                                            基因ID
- 115704
- 
                                            UniProt
- Q96CN4
 抗原
- 
                    
 
                                     
                                     
                                    